Preclinical studies have indicated that ADCC contributes to the anti-HER2+ tumor effects of trastuzumab [10]; However, there are few data on the prognostic role of immune cells for survival in HER2-positive breast cancer patients [11]. This evidence concerns the gene ERBB2 and breast carcinoma.